• Mashup Score: 0

    July 21, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i  announced that enrollment is complete in the SmartfIRE study designed to evaluate the safety and efficacy of its investigational THERMOCOOL SMARTTOUCH SF Dual Energy Catheter and investigational TRUPULSE Generator for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (AFib) during standard electrophysiology mapping and ablation procedures.[i] The catheter and the generator are fully integrated with the CARTO 3 Advanced 3D Imaging System.  SmartfIRE is a pivotal, prospective, multi-center, single-arm study evaluating Biosense Webster’s dual energy pulsed field (PF) and radiofrequency (RF) ablation system. Since the study’s commencement in February 2023, the trial has enrolled 149 patients with paroxysmal AFib across nine centers in Europe. Patients will be assessed for 12 months for safety and efficacy.1  “Biosense Webster’s dual ener

    Tweet Tweets with this article
    • @DAICeditor @BiosenseWebster #SmartfIRE study is evaluating #THERMOCOOL #SMARTTOUCH SF Dual Energy Catheter’s potential to enable safe and simple procedures with the ability to deliver both radiofrequency (#RF) and pulsed field ablation (#PFA): https://t.co/DQH9VVgk0w

  • Mashup Score: 0

    May 15, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that data from 28 company-sponsored and funded studies, including one late breaker, will be presented at Heart Rhythm 2023, the Heart Rhythm Society’s annual meeting, taking place in New Orleans, Louisiana May 19-21. Presentation topics include new data in…

    Tweet Tweets with this article
    • @DAICeditor @BiosenseWebster Presentations include data on pulsed field ablation (#PFA), disparities in atrial fibrillation (#AFib) management, and role of mapping and digital technologies in advancing #cardiac #arrhythmia treatment: https://t.co/z5sJVTrtOB #HRS2023

  • Mashup Score: 0

    July 20, 2022 — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial fibrillation (Afib), today announced several milestones toward the development of a next generation pulse field ablation (PFA) technology for treatment of AFib, including the formation of a clinical advisory board, filing of key patents and completing initial pre-clinical studies.   …

    Tweet Tweets with this article
    • @DAICeditor @CardioFocusAF CardioFocus announced several #milestones toward the development of a next generation #pulsefieldablation (#PFA) #technology for treatment of #AFib: https://t.co/lrCYetfKsq